R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

Brighter times ahead for biotech in 2024?

The biotech industry experienced heady highs in early 2021, but has since suffered from a tight financial climate that has brought bankruptcies and widespread redundancies.

R&D

A clearer harmony and attractiveness for EU Clinical Trials ...

EU Clinical Trials Regulation (EU CTR) has been a hot topic for a little while now.

R&D

Changing Faces: Pharma and biotech hires from January 2024

It’s a new year, so we’re kicking it off with the relaunch of Changing Faces after we lost the thread a bit last year.

R&D

JP Morgan 2024 – Katherine Stueland

Diagnostics can be a neglected part of the treatment paradigm, but it’s hugely important for connecting patients with the right treatments.

R&D

Making connections and getting noticed as a biotech start-up...

A thriving start-up ecosystem is essential to the health of the modern life sciences industry, as it provides an incubator for innovative ideas that might be too high-risk for larger, more

R&D